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Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing
chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial
chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the
same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent
chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus
docetaxel who reached a serum prostate-specific antigen (PSA) o4ngml
 1 (22% of the 37 patients who were initially treated with
this regimen). Chemotherapy was suspended until a rise in PSA X50% and 1ngml
 1. The median duration of the first treatment
holiday was 20 weeks (13–74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second
chemotherapy holiday, and the median duration was 21 weeks (17–28 weeks). Two patients elected to take a third chemotherapy
holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6–29.4 months), and the
median survival is 41 months (95% CI 33.7–48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically
meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent
chemotherapy for AIPC is feasible and deserves further study.
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The optimal duration of chemotherapy for androgen-independent
prostate cancer (AIPC) remains uncertain. Recently, a survival
benefit for treatment with docetaxel-containing chemotherapy was
demonstrated in two large phase III clinical trials (Eisenberger
et al, 2004; Petrylak et al, 2004). Patients were treated for a fixed
number of cycles and their total treatment lasted 30 and 36 weeks
in these two studies. As these studies are likely to define the
standard of care in metastatic AIPC, it is likely that patients who
receive a recommendation for chemotherapy will be treated for a
fixed number of cycles and a significant fraction of these patients
will be responding to treatment when they complete the initial
course of chemotherapy.
Available studies provide no guidance regarding the treatment
of these patients after an initial course of therapy is completed.
Indeed, relatively little information about retreatment with the
same chemotherapy after a robust initial response to treatment in
any tumour type is available. In a recent review, Cara and Tannock
identified 15 published reports of retreatment after initial complete
response in a range of solid and haematologic malignancies.
Response rates to retreatment with the same regimen ranged from
18 to 100%. None of these studies included prostate cancer patients
(Cara and Tannock, 2001).
We previously reported that a single, clinically meaningful
chemotherapy holiday was feasible and was associated with quality
of life gains in a select group of patients who responded well to
initial docetaxel-containing chemotherapy (Beer et al, 2003b). We
now provide longer-term outcome information about these
patients and report our experience with multiple cycles of
chemotherapy interrupted by treatment holidays.
In the context of a phase II clinical trial of high-dose calcitriol
and docetaxel in AIPC, we developed and prospectively evaluated
an intermittent chemotherapy protocol. The rationale for calcitriol
plus docetaxel has been previously described (Beer et al, 2003a)
and outcomes with the first chemotherapy holiday were previously
reported (Beer et al, 2003b). This report is focused on long-term
outcome in patients treated with intermittent chemotherapy.
MATERIALS AND METHODS
Detailed eligibility criteria and treatment regimen have been
previously reported (Beer et al, 2003a). Men with chemotherapy-
naı ¨ve, metastatic AIPC were treated with calcitriol (Rocaltrol
s
0.5mg capsules, Roche Pharmaceuticals, Nutley, NJ) 0.5mgkg
 1 on
day 1, followed by docetaxel (Taxotere
s, Aventis Pharmaceuticals,
Bridgewater, NJ) 36mgm
 2 intravenously over 15–30min on day
2 of each treatment week. Dexamethasone 8mg orally was given 12
and 1h prior to and 12h after docetaxel. Treatment was
administered weekly for 6 consecutive weeks on an 8-week cycle.
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lPatients who met criteria for prostate-specific antigen (PSA)
response (50% reduction confirmed 4 weeks apart) and reached a
serum PSAo4ngml
 1 were eligible for intermittent chemother-
apy. During the chemotherapy holiday, a serum PSA and clinical
examination was performed every 4 weeks. Imaging was repeated
every 8 weeks in patients with measurable disease. Chemotherapy
was resumed after a confirmed PSA increase of 50% and of at least
1ngml
 1 (modified to 2ngml
 1 during the course of the study) or
for any other evidence of disease progression.
After chemotherapy was resumed, patients whose response to
retreatment allowed them to meet eligibility criteria again could
have additional chemotherapy holidays. The number of such
holiday and retreatment cycles was not restricted. The study was
approved by the IRB of the Oregon Health & Science University
and Portland VA Medical Center. Informed consent was obtained
from all participants.
RESULTS
Of 37 patients, 11 met eligibility for intermittent chemotherapy
after responding to initial treatment, which lasted for a median of
45 weeks (range 25–53 weeks). Except for having a lower serum
PSA at study entry, these 11 patients did not differ from the
remaining 26 patients and their characteristics have been
previously published (Beer et al, 2003b). Nine patients consented
to intermittent chemotherapy. One patient was removed from the
study for reasons unrelated to prostate cancer or its treatment.
Therefore, eight patients were evaluable for outcome with
intermittent chemotherapy. Baseline characteristics of these eight
patients are reported in Table 1.
First chemotherapy holiday
The median duration of the first treatment holiday was 20 weeks
(range 13–74 weeks). All patients resumed therapy as a result of a
rising PSA. After resumption of therapy, five patients experienced
a confirmed 50% reduction in serum PSA from their postholiday
measurement, while three had stabilisation of the serum PSA for at
least 24 weeks (range 24–56 weeks). Two patients had measurable
disease. Both of these entered the break after a partial response
(PR) and retained PR status throughout the treatment holiday.
Second chemotherapy holiday
Only the patients who had a confirmed 50% reduction in serum
PSA in response to their second course of chemotherapy met
eligibility criteria for a second chemotherapy holiday. One of these
five patients died of unrelated causes. Therefore, four patients
participated in a second chemotherapy holiday. The median
duration of the second holiday was 21 weeks (range 17–28 weeks).
Two of these patients experienced a confirmed 50% reduction in
serum PSA from their postholiday measurement in response to the
third course of chemotherapy. The other two declined a third
round of chemotherapy, one because of persistent treatment-
related pleural effusions and the other due to patient preference.
Third chemotherapy holiday
The third treatment holiday lasted 10 and 26 weeks. The
experience of a patient who has completed three chemotherapy
holidays is shown in Figure 1.
Overall, the median time to treatment failure from the first day
of chemotherapy in these eight patients was 26.5 months (95% CI
23.6–29.4 months). Five of the eight patients are alive and the
Kaplan–Meier estimate for median survival is 41 months (95% CI
33.7–48.3 months).
DISCUSSION
While durable complete remission remains an elusive goal in the
treatment of AIPC, substantial responses to therapy are frequently
reported. The optimal approach to the treatment of AIPC patients
with a substantial response to initial chemotherapy remains
unclear. We previously reported that retreatment with the same
regimen after a single chemotherapy holiday was feasible in such
patients, that the chemotherapy holiday was long enough to be
clinically meaningful, and that chemotherapy holidays were
associated with improvements in common chronic toxicities of
chemotherapy.
With longer follow-up, we report here that one half of the
patients who chose intermittent chemotherapy were able to
continue this treatment approach beyond one cycle. We conclude
that in selected patients, multiple courses of docetaxel-based
chemotherapy interrupted by chemotherapy holidays are feasible.
Additional study is needed to definitively determine the contribu-
tion of intermittent chemotherapy to the overall efficacy and
toxicity of treatment.
Table 1 Patient characteristics prior to starting chemotherapy
Characteristic
Patients who consented to
intermittent therapy
No. of patients 8
Age (years)
Median (range) 74 (68–81)
ECOG Performance Status
05
12
21
PSA (ngml
 1)
Median (range) 15 (6–553)
Site of metastases
Bone only 6
Bone and lymph nodes 1
Lymph nodes only 1
Prior radiation
External beam to primary 4
External beam to metastases 1
Radiopharmaceuticals 0
No. of prior hormonal treatments
Median (range) 2 (1–3)
PSA¼prostate-specific antigen.
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Figure 1 Changes in serum PSA over time in a patient treated with
intermittent chemotherapy. Closed arrows indicate when chemotherapy
was initiated and open arrows show when chemotherapy was stopped.
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